Original version

BBC World Service News Internet

The Inquiry

Documentaries

Factual

News

Getting beyond the headlines to explore the forces and ideas shaping the world

The Inquiry gets beyond the headlines to explore the trends, forces and ideas shaping the world.

No Master Brand

BBC World Service Australasia

BBC World Service East and Southern Africa Schedule

BBC World Service East and Southern Africa

BBC World Service Online

BBC World Service schedule for American satellite radio and the Caribbean

BBC World Service Americas and the Caribbean

BBC World Service

BBC World Service South Asia

BBC World Service Europe and the Middle East

BBC World Service West and Central Africa Schedule

BBC World Service West and Central Africa

BBC World Service East Asia

BBC Afghan Radio

The Inquiry: Have we reached a turning point with migraine medication?

Have we reached a turning point with migraine medication?

30/11/2023 GMT

BBC World Service - The Inquiry, Have we reached a turning point with migraine medication?

Could a new class of drugs change the lives of those living with migraine?

Could a new class of drugs developed specifically to target migraine, change the lives of those living with the condition?

Around 1 billion people around the world suffer from a mysterious neurological condition called migraine. Far more than just a headache, migraine is abnormal processing of the world around us that can have symptoms like loss of sight and speech, dizziness, nausea and extreme fatigue.

There are drugs which can help those struggling with the condition like anti-depressants and anti-convulsants. However, they weren’t developed specifically for migraine and can come with quite a lot of side effects or simply not work.

For a long time migraine medication has been a process of trial and error. 

But a new class of drugs called anti-CGRPs are being hailed as a breakthrough migraine medication. Anti-CGRPs have a small side effect profile and were designed specifically to target migraine. They work by blocking CGRP (Calcitonin Gene-Related Peptide) from building up in the body and triggering a receptor in the brain which turns on a head pain pathway causing the migraine attack.

Earlier this year the National Institute of Health and Care Excellence - or NICE – in England cleared the use of an anti-CGRP called Rimegepant to use as both a preventive and acute treatment. Clinicians are hoping this will massively improve the lives of those living with the condition.

So this week on The Inquiry were asking ‘Have we reached a turning point with migraine medication?’


Contributors: 
Dr. Amaal Starling, neurologist and headache specialist at Mayo Clinic in Scottsdale, in the US state of Arizona. 
Dr Faraidoon, researcher at the Georgian Institute for Global Health at the University of New South Wales, Sydney, Australia.
Peter Goadsby , Director of the NIHR King's Clinical Research Facility and a professor of neurology at King's College London, England. 
Dr Lise Rystad Oie, researcher at the government funded Norwegian Centre for Headache Research - also known as NorHead.


Presenter: Charmaine Cozier  
Producer: Anoushka Mutanda-Dougherty 
Editor: Tara McDermott   
Researcher: Matt Toulson
Technical Producer: Craig Boardman
Broadcast Co-ordinator: Jordan King

Image: eternalcreative - Getty Images: 1372323487

Accessibility links

Programme Index

The Inquiry

Have we reached a turning point with migraine medication?

Genres

Formats

Brand

BBC World Service News Internet

About BBC World Service